24 Apr 2017   |   News   |   Update from Amgen
These updates are republished press releases and communications from members of the Science|Business Network

Amgen enters agreement to develop outcomes-based contracts

Amgen has sealed an agreement with Inovalon, a specialist in health data analytics, to develop outcomes based contracts based on the value of Amgen’s products.

The agreement will focus specifically on rheumatoid arthritis, a chronic, high-cost autoimmune disease affecting more than two million Americans. As the healthcare landscape continues to rapidly transform from fee-for-service and volume-based models, to value and outcomes-based models, outcomes-based contracts have become increasingly prevalent in the marketplace.

Inovalon’s outcomes-based contracting platform supports the creation, deployment and management of value-based contracts between payers and life sciences companies, using data aggregation and management, predictive analytics, data-driven patient and provider engagement platforms, and data reporting capabilities.



Never miss an update from Science|Business:   Newsletter sign-up